Patent ID: 11951105
Assignee: LAKE O'HARA LLC
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 16:
17. A method of initiating adjunctive treatment of major depressive disorder with brexpiprazole in an obese patient who is not a CYP2D6 poor metabolizer, comprising:
(a) administering either 0.5 or 1 mg brexpiprazole twice daily on each of the first 7 days of brexpiprazole treatment;
(b) administering double the individual brexpiprazole dose of step (a) once daily on each of the next 7 days following step (a); and then
(c) administering the recommended daily dose of brexpiprazole once daily thereafter;, wherein the obese patient has one or more of the following characteristics:
(i) BMI of at least about 35;
(ii) % IBW of at least about 150%;
(iii) waist size greater than about 42 inches;
(iv) % body fat greater than about 40%;
(v) % android body fat greater than about 40%;
(vi) % gynoid body fat greater than about 40%; or
(vii) total body fat greater than about 40 kg.